拉莫三嗪与喹硫平治疗双相抑郁的对照研究

目的比较拉莫三嗪(利必通)和喹硫平(思瑞康)治疗双相抑郁的疗效及安全性。方法对71例符合CCMD-3诊断双相障碍(目前为抑郁发作)的患者按随机、平行、对照的方法分为拉莫三嗪组和喹硫平组,观察8周,分别于第0、2、4、6、8周末用HAMD、CGI评价疗效,于第2、4、6、8周末用TESS评定不良反应,于第4、8周末用BRMS评定躁狂症状。结果拉莫三嗪组的痊愈率34.21%,有效率65.79%,喹硫平组的痊愈率39.39%,有效率69.70%。两组疗效比较无显著性差异(P>0.05),两组不良反应发生率相当。结论拉莫三嗪和喹硫平均可首选用于双相抑郁治疗,且安全性、不良反应相当。

A controled study of lamotrigine Versus quetiapine in the treatment of bipolar depression

OBJECTIVE To compare both the efficacy and safety of lamotrigine（Lamictal） and quetiapine（Seroquel） in the treatment of bipolar depression.METHODS 71 patients who met the CCMD-3 diagnosis of bipolar disorder（currently depressive episode） were divided into lamotrigine group and quetiapine group in a randomized,parallel and controlled way.During the 8 weeks′ observation,assess the therapeutic effects at the end of the 0,2,4,6,8 week respectively,with HAMD and CGI.Evaluate the adverse reactions at the end of the 2,4,6,8 week respectivelywith TESS and the manic symptoms at the end of the 4 and 8 week with BRMS.RESULTS The cure rate and effectve rate of lamotrigine group are 34.21% and 65.79%,and 39.39% and 69.70% in quetiapine group.There was no significant difference（P0.05） between the two groups,which means that their adverse reaction rates were generally equivalent.CONCLUSION Lamotrigine and quetiapine are preferred for the treatment of bipolar depression,and have equivalent safety and adverse reactions.